Generalized Anxiety Disorder

Psychedelic-Assisted Therapy Advancements Create A New Horizon For Mental Health In Colorado

MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials

Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety

MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials

Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety

MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued

Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed

MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued

Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed

MindMed's Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone

MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected

Generalized Anxiety Disorder Recent News

Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004.

Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder

Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.

Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing

Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect

Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results

Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ:

Psychedelics Companies Join The Race To Develop Much-Needed Anxiety Treatment

Life sciences biotech company Cybin Inc. (NYSE: CYBN) announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its proprietary deuterated DMT molecule, CYB004.

Where Are Psychedelics Headed In 2023? These Two Heavy Hitters Share Their Plans

It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year.

These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year

What a year for psychedelics!

MindMed's First Patient Dosing Clinical Trial With LSD For Treatment Of Generalized Anxiety Disorder

The clinical-stage biopharma company Mind Medicine -also known as MindMed (NASDAQ: MNMD), which recently made headlines reg